FGFR1 and breast cancer: Moreover, through the use of an in vivo mouse model with FGFR1-amplified BC primary xenograft (HBCx-3), the authors showed that the tumor regressed after treatment with 50 mg/kg of dovitinib, compared to mice treated with just a vehicle control (p < 0.001) [67].